Brochure
Antibody Lead Optimization Service
Antibody Lead
Optimization Service
Accelerating the acquisition of "me-better"
antibody candidates
Antibody Lead Optimization Service
Accelerating the acquisition of "me-better" antibody candidates
Empowered by a robust bioinformatics platform, ProBio offers customers comprehensive antibody
engineering services, including antibody humanization, affinity maturation, Fc engineering, and
developability optimization, to obtain "me-better" antibody leads.
Two primary considerations in the preclinical development of antibody drugs: Functionality
and Developability. ProBio conducts antibody optimization to improve these two
properties:
Developability
Functionality
Antibody humanization
Antibody affinity maturation
Success in delivering 700+ projects
Guarantee no affinity loss
Fast turnaround time of 2.5 weeks
Experience with 280+ projects
Guarantee > 10-fold affinity improvement
Delivery as fast as 8 weeks
Antibody developability optimization
Fc engineering
Immunogenicity, post-translational
modifications(PTM), and antibody aggregation
Developability prediction, optimization, and
assessment
ADCC, CDC, ADCP enhancement
STR Fc silencing technology
Half-life extension.
One-stop solution from sequence design
to pharmacology study
Technical support by the CMC team
Empowered by Bioinformatics Platform
Robust bioinformatics tools comprise multiple databases and AI-powered WeMol platform to build an
incorporated computer-aided molecular design platform.
1
Antibody Humanization Service
Experience with 700+ projects (Noted: the most advanced project has been marketed ）.
Guarantee no affinity loss, humanization rate >95%
Multiple detection systems: SPR, ELISA, FACS, suitable for mAb, scFv, and sdAb
Developability prediction reports to illustrate PTM, aggregation, and immunogenicity data.
Express Package
Deluxe Package
As Fast as 2.5 Weeks to Get Your
Antibody Humanized
Get Humanized Antibody with No
Affinity Loss
CDR grafting and back mutation technologies
enable the express package to produce
humanized antibodies with high expression
levels, good thermal stability, and comparable
affinity with the parental antibodies in 2.5
weeks.
Choice of the deluxe package allows users to
obtain the humanized antibodies without
affinity loss via CDR grafting, back mutation,
and FASEBA (Fast Screening for Expression,
Biophysical-properties, and
Affinity) high-throughput screening
technology in 8 weeks.
Developability
analysis
Sequence
mAb sequencing
and binding
confirmation
Human germline
analysis, CDR,
FR, canonical
interface
PTM, aggrega-
tion, and
CDR grafting
acceptor
selection
immunogenicity
Homology
structural
modeling, back
mutation library
design
Phage display/-
FASEBA
screening
Humanized lgG
characterization
Humanized lgG
production
Affinity ranking
Fig1. workflow of antibody humanization
Steps only deluxe package
Case study: FACS Determination
FACS to compare the binding ability between
humanized and chimeric antibodies. The same binding
profile was observed based on the FACS results.
Fig2.Comparison of the affinity of humanized
antibodies to parental antibody
2
Antibody Affinity Maturation Service
A guarantee of > 10-fold affinity improvement
Suitable for mAb, scFv and sdAb
AI-powered WeMol platform
Proprietary precise mutagenesis library
(PML) and FASEBA screening technology
Experience with 220+ projects
1
AI-powered WeMol Platform
WeMol integrates advanced AI with molecular dynamics simulations and other
physics-based methods to enable deeper conformational sampling and improve
structure prediction accuracy.
2
Precise Mutagenesis Library (PML) Platform
PML is a site-saturation mutagenesis library
that scans the mutation site in a saturation
manner to comprise a saturation scanning
mutagenesis library.
Each amino acid is mutated into the other 18
amino acids except Cystein with the same
distribution.
Fig 3. Precise Mutagenesis Library (PML)
FASEBA High-throughput Screening Platform
3
FASEBA is a proprietary E.Coli based system.
FA Fast
It is used to select the best protein binders
from a considerable number of protein
candidates in a high throughput fashion
without purifying these proteins.
S
Screening of
Expression
Biophysical-properties and
Affinity
E
B
A
Fig 4. FASEBA High-throughput Screening
Case study
The affinity of an antibody improved at various
levels, as shown in the data of SPR analysis.
The top candidate, variant 2, showed a
163-fold improveDment in K (10-10 to 10-12 molar)
Fig 5. SPR analysis
3
Fc Engineering Service
Fc engineering service：
One-stop Fc domain solution from
sequence design to pharmacology
study
Fc silence
√
√
√
ADCC,CDC, ADCP enhancement
Half-life extension
Case study 1: STR silencing
technology
A cell-based reporter assay (Fig 6a) showed that the
STR variant had no activity on all FcγRs compared to
wild-type IgG1, LALA, and aglycosylated variants. A
cytokine release assay with PBMCs isolated from
healthy donors showed (Fig 6b) that STR exhibited
no significant activity above buffer alone for all
cytokine measured. STR silencing technology truly
abolishes the Fc domain effector function.
a
b
* Data comes from mbsolve
Fig 6. Cell-based assay for different Fc silence mutants
Case study 2: ADCC and CDC
enhancement
The potency of ADCC and CDC against PA-1 target
cells of two mutated Fc constructs was evaluated. As
claimed, the published Fc mutation sequences showed
enhanced ADCC and CDC activities on PA-1 cells.
Fig 7. Cell-based assay for different Fc mutants
Antibody Developability Optimization Service
One-stop developability solution from prediction to optimization
PTM optimization: Guarantee no affinity loss
Antibody aggregation optimization: guarantee at least 5-fold yield improvement
The developability prediction enables Probio further to optimize the sequence of PTM sites and
hydrophobic regions to obtain antibody candidates with better developability.
Optimization
Prediction
PTM site optimization
Developability
PTM analysis
PTM removal
Ab testing report
Ab validation
Prediction Report
immunogenicity
PTM
antibody aggregation
Antibody Aggregation Optimization
Antibody sequence
Antibody expression
and modeling analysis
4
ProBio Inc.
Building 9, 311 Pennington Rocky Hill Rd,
Pennington, NJ